<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chen KZ</submitter><funding>National Natural Science Foundation of China</funding><pagination>78</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12604166</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Tenascin-C (TNC) is an extracellular matrix (ECM) protein involved in tissue damage and fibrosis. Chimeric antigen receptor (CAR) cell therapy is a novel therapeutic approach that has attracted increasing attention in recent years. Here, we engineered CAR-macrophages targeting TNC (TNC-CAR-Ms) and explored the underlying mechanism through which TNC-CAR-Ms treat liver fibrosis.&lt;h4>Methods&lt;/h4>The role of TNC in liver fibrosis was studied in established Tnc knockout (KO) and littermate control mice. A TNC-targeted single-chain variable fragment (scFv) was designed to generate TNC-CAR-Ms and evaluate their biological function. The phagocytosis and killing effects of TNC-CAR-Ms were tested in vitro, while the antifibrotic efficacy and safety of TNC-CAR-Ms were evaluated in v</pubmed_abstract><journal>Military Medical Research</journal><pubmed_title>TNC-targeted CAR-macrophage therapy alleviates liver fibrosis in mice.</pubmed_title><pmcid>PMC12604166</pmcid><funding_grant_id>82204500</funding_grant_id><funding_grant_id>82072697</funding_grant_id><pubmed_authors>Zhang W</pubmed_authors><pubmed_authors>Huo YK</pubmed_authors><pubmed_authors>Zhou YX</pubmed_authors><pubmed_authors>Fu Q</pubmed_authors><pubmed_authors>Ma XD</pubmed_authors><pubmed_authors>Zhang SS</pubmed_authors><pubmed_authors>Wan HY</pubmed_authors><pubmed_authors>Gao ZQ</pubmed_authors><pubmed_authors>Lin ZY</pubmed_authors><pubmed_authors>Chen KZ</pubmed_authors><pubmed_authors>Chen LJ</pubmed_authors><pubmed_authors>Cheng HW</pubmed_authors></additional><is_claimable>false</is_claimable><name>TNC-targeted CAR-macrophage therapy alleviates liver fibrosis in mice.</name><description>&lt;h4>Background&lt;/h4>Tenascin-C (TNC) is an extracellular matrix (ECM) protein involved in tissue damage and fibrosis. Chimeric antigen receptor (CAR) cell therapy is a novel therapeutic approach that has attracted increasing attention in recent years. Here, we engineered CAR-macrophages targeting TNC (TNC-CAR-Ms) and explored the underlying mechanism through which TNC-CAR-Ms treat liver fibrosis.&lt;h4>Methods&lt;/h4>The role of TNC in liver fibrosis was studied in established Tnc knockout (KO) and littermate control mice. A TNC-targeted single-chain variable fragment (scFv) was designed to generate TNC-CAR-Ms and evaluate their biological function. The phagocytosis and killing effects of TNC-CAR-Ms were tested in vitro, while the antifibrotic efficacy and safety of TNC-CAR-Ms were evaluated in v</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-05T12:52:39.37Z</modification><creation>2026-05-17T03:07:53.479Z</creation></dates><accession>S-EPMC12604166</accession><cross_references><pubmed>41214839</pubmed><doi>10.1186/s40779-025-00667-3</doi></cross_references></HashMap>